AU2001233099A1 - Crystallization and structure determination of staphylococcus aureus nad synthetase - Google Patents

Crystallization and structure determination of staphylococcus aureus nad synthetase

Info

Publication number
AU2001233099A1
AU2001233099A1 AU2001233099A AU3309901A AU2001233099A1 AU 2001233099 A1 AU2001233099 A1 AU 2001233099A1 AU 2001233099 A AU2001233099 A AU 2001233099A AU 3309901 A AU3309901 A AU 3309901A AU 2001233099 A1 AU2001233099 A1 AU 2001233099A1
Authority
AU
Australia
Prior art keywords
crystallization
staphylococcus aureus
structure determination
nad synthetase
aureus nad
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001233099A
Inventor
Timothy E. Benson
Donald Bryan Prince
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Pharmacia and Upjohn Co
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn Co, Upjohn Co filed Critical Pharmacia and Upjohn Co
Publication of AU2001233099A1 publication Critical patent/AU2001233099A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/25—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/20—Protein or domain folding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/50—Molecular design, e.g. of drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/305—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F)
    • G01N2333/31—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
AU2001233099A 2000-01-31 2001-01-30 Crystallization and structure determination of staphylococcus aureus nad synthetase Abandoned AU2001233099A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17926100P 2000-01-31 2000-01-31
US60/179,261 2000-01-31
PCT/US2001/002913 WO2001055443A1 (en) 2000-01-31 2001-01-30 Crystallization and structure determination of staphylococcus aureus nad synthetase

Publications (1)

Publication Number Publication Date
AU2001233099A1 true AU2001233099A1 (en) 2001-08-07

Family

ID=22655850

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001233099A Abandoned AU2001233099A1 (en) 2000-01-31 2001-01-30 Crystallization and structure determination of staphylococcus aureus nad synthetase

Country Status (3)

Country Link
US (1) US6988041B2 (en)
AU (1) AU2001233099A1 (en)
WO (1) WO2001055443A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1627323A4 (en) * 2003-05-06 2008-04-09 New Century Pharmaceuticals Albumin binding sites for evaluating drug interactions and methods of evaluating or designing drugs based on therir albumin binding properties
US20070043509A1 (en) * 2003-11-03 2007-02-22 Carter Daniel C Albumin binding sites for evaluating drug interactions and methods of evaluating or designing drugs based on their albumin binding properties
US20090215627A1 (en) * 2004-08-06 2009-08-27 Yang Shen Crystal Structure of Biotin Carboxylase (Bc) Domain of Acetyl-Coenzyme a Carboxylase and Methods of Use Thereof
CA2626262C (en) 2005-10-18 2015-09-08 Homme W. Hellinga Rationally-designed meganucleases with altered sequence specificity and dna-binding affinity
US7471770B2 (en) * 2006-01-12 2008-12-30 Siemens Aktiengesellschaft Radioscopy device
WO2007136744A1 (en) * 2006-05-19 2007-11-29 The Johns Hopkins University Crystal structure of a substrate complex of nampt/pbef/visfatin
CN100465643C (en) * 2007-03-19 2009-03-04 南开大学 Novel methods for high efficiency and rapid getting fine three dimensional structure of target protein composite body and target molecule target molecule
CN112466413B (en) * 2020-12-04 2024-04-12 南通海智医药科技有限公司 Molecular regulation and control method for specific crystal form of small molecular medicine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993002209A1 (en) * 1991-07-22 1993-02-04 The Regents Of The University Of California Methods of designing specific affectors using three-dimensional conformation of enzyme/affector complex
AU1115797A (en) * 1995-10-26 1997-05-15 Alessandra D'azzo Protective protein/cathepsin a and precursor: crystallization, x-ray diffraction, three-dimensional structure determination and rational drug design
WO2001016292A2 (en) 1999-09-01 2001-03-08 Human Genome Sciences, Inc. 37 staphylococcus aureus genes and polypeptides
US6737248B2 (en) * 1996-01-05 2004-05-18 Human Genome Sciences, Inc. Staphylococcus aureus polynucleotides and sequences
US6093573A (en) * 1997-06-20 2000-07-25 Xoma Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
CA2317439A1 (en) * 1998-01-14 1999-07-22 Wayne J. Brouillette Methods of synthesizing and screening inhibitors of bacterial nad synthetase enzyme, compounds thereof, and methods of treating bacterial and microbial infections with inhibitors of bacterial nad synthetase enzyme
JP2002516068A (en) 1998-03-20 2002-06-04 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド Staphylococcus aureus gene and polypeptide
AU6131999A (en) 1998-09-01 2000-03-21 Human Genome Sciences, Inc. (staphylococcus aureus) genes and polypeptides

Also Published As

Publication number Publication date
WO2001055443A9 (en) 2003-01-16
WO2001055443A1 (en) 2001-08-02
US20030166233A1 (en) 2003-09-04
US6988041B2 (en) 2006-01-17

Similar Documents

Publication Publication Date Title
AU4826300A (en) Multiple round game of change
AU2609901A (en) Antimicrobial compositions and methods of use
AU2002333394A1 (en) Fungicide active substance combinations
AU2001264671A1 (en) Latency monitor
AU2001272383A1 (en) Fungicidal combinations of active agents
AU2001233099A1 (en) Crystallization and structure determination of staphylococcus aureus nad synthetase
AU2001275918A1 (en) Biocide compositions and methods and systems employing same
AU1572101A (en) Admixture of linezolid and other antibacterial agents
AU2001288092A1 (en) Method of crystallization
AU6339499A (en) Quinolones as t-rna synthetase inhibitors and antibacterial agents
AU2002216223A1 (en) Preservation of cells
AU2001286852A1 (en) Quinoline antibacterial compounds and methods of use thereof
AU2001264432A1 (en) Velocity measurement - center of gravity
AU2001249786A1 (en) Crystallization and structure determination of staphylococcus aureus thioredoxin reductase
AU3716800A (en) Placemat having antimicrobial agent
AU2001249561A1 (en) Antimicrobial compound
AU6391500A (en) Use of the crystal structure of staphylococcus aureus isoleucyl-trna synthetase in antibiotic design
AU6102899A (en) Production and use of antimicrobial agents
AU2002226212A1 (en) Compositions and methods involving staphylococcus aureus protein STAAU-R9
AU2003245183A1 (en) Derivatives of rifabutine useful as antimicrobial agents
AU2001262148A1 (en) Use of 3-iodine-2-propinyl-carbamates as antimicrobial active agent
AU2002216249A1 (en) Antimicrobial agents
AU2001251370A1 (en) Antimicrobial methods and materials
AU7164701A (en) Crystallization and structure of staphylococcus aureus peptide deformylase
AU2002257451A1 (en) Individualization of therapy with antibiotic agents